Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

COVID-19 vaccine programmes are expected to cost poorer countries an additional 56.6% on health budgets, compared with just 0.8% on wealthy countries’ health expenditure, according to new data from the United Nations Development Programme (UNDP), the World Health Organisation (WHO) and the University of Oxford.

Vaccine being administrered

According to the research, inequity will have a 'lasting and profound impact' on socio-economic recovery in low and lower-middle income countries unless there is urgent action to make vaccines affordable and accessible to everyone.

With the current cost of vaccines calculated at an average US$15.80, and without immediate global financial support, low-income countries are forecast to see health costs soar by more than half, to vaccinate fully a target of 70% of their populations. But high-income countries would have to increase spending by just 0.8 percent to achieve the same results. This would account for half of low-income countries' projected GDP growth in 2021, against 0.2% for high-income countries.

These insights come from the Global Dashboard on Vaccine Equity , a joint initiative from UNDP, WHO and Oxford’s Blavatnik School of Government, which combines the latest COVID-19 vaccination information with the most recent socio-economic data. It illustrates why vaccine equity is not only critical to saving lives but also to driving a fairer and faster recovery from the pandemic.

Read the full story on the University of Oxford website.

Similar stories

Oxford vaccine reaches one billion doses released

The University of Oxford’s and our partners AstraZeneca have today announced that one billion doses of the ChAdOx1 nCov-19 coronavirus vaccine have been released, to more than 170 countries, marking a key milestone as part of the University and AstraZeneca’s joint vision to make the available to the world, on a not-for-profit basis for the world during the pandemic, and in perpetuity for low- and middle-income countries.

Research programme tackling COVID-19 variants of concern receives funding boost

A gift from the Red Avenue Foundation will enable the expansion of a major research programme aimed at rapidly identifying and interrogating emerging COVID-19 variants.

Phase I trial begins of new vaccine against the Plague

Researchers at the University of Oxford today launched a Phase 1 trial to test a new vaccine against plague.

New therapeutic targets identified in the treatment of psoriatic arthritis

Researchers identify two inflammatory-driving proteins, osteopontin and CCL2, highly expressed in psoriatic arthritis joints.

Treatment choice for rotator cuff disorders could create efficiency and savings for the NHS

A trial that evaluated the clinical and cost effectiveness of physiotherapy treatments for rotator cuff disorders suggests cost savings can be made while maintaining positive patient outcomes.